# Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis

> **NCT02201043** · PHASE2 · COMPLETED · sponsor: **Shanghai Pharmaceuticals Holding Co., Ltd** · enrollment: 197 (actual)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Thalidomide 150mg
- **DRUG:** Thalidomide 100mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02201043
- **Lead sponsor:** Shanghai Pharmaceuticals Holding Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2015-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201043, "Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02201043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*